TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7738436
Drug: Colored overlays
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colored overlays or lenses (e.g., Irlen lenses)
Study: 8095507
Drug: Nicardipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (30 mg three times daily)
Study: 6107945
Drug: DL-308 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-308 (10 mg)
Study: 6107945
Drug: DL-308 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-308 (20 mg)
Study: 6107945
Drug: Thioridazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (50 mg)
Study: 6107945
Drug: DL-308 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-308 (10 mg) vs Thioridazine (50 mg)
Study: 6107945
Drug: DL-308 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-308 (10 mg) and Thioridazine (50 mg)
Study: 28588793
Drug: L-Glutamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine (10 g orally three times daily)
Study: 28588793
Drug: L-Glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine
Study: 26109814
Drug: Autologous CD34(+)
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CD34(+) cell infusion
Study: 26109814
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment for liver cirrhosis
Study: 23063301
Drug: eszopiclone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: eszopiclone (all doses)
Study: 19242916
Drug: Restorative yoga
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restorative yoga (RY) intervention (10 weekly 75-minute classes)
Study: 15007319
Drug: Intra-articular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular ketamine (0.5 mg/kg)
Study: 11247525
Drug: Keys to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keys to Caregiving program delivered by 6-weekly visits
Study: 11247525
Drug: Control program
Normalized name: ZO Skin Health Pigment Control Program Plus Hydroquinone KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control program consisting of 6-weekly neutral visits
Study: 8021573
Drug: Felodipine 10-20
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10-20 mg once daily for four weeks
Study: 23740664
Drug: PDT +
Normalized name: Photodynamic Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT + surgery (4 sessions of topical PDT mediated with 20% 5-aminolevulinic acid)
Study: 16117956
Drug: Daily visits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily visits for 1 month
Study: 16117956
Drug: Weekly visits
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly visits
Study: 9199724
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment based on a psychodynamic approach (PT)
Study: 1391144
Drug: Cisapride 30
Normalized name: cisapride 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 30 mg/daily for two months
Study: 1391144
Drug: Sucralfate 4
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate 4 g/daily for two months
Study: 3900900
Drug: Hydralazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (2 mg/kg/day) for 3 days
Study: 18032997
Drug: Vaginal lubricants
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal lubricants (2 types of gels, suppositories) in addition to male and female condoms
Study: 3933197
Drug: NaCl infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaCl infusion (control group during crossover study)
Study: 23792625
Drug: cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: cTnT levels ≥0.01 ng/ml
Study: 15314987
Drug: Ticlopidine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (125 mg twice every 24h)
Study: 10229733
Drug: DCLHb (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb (25, 50, and 100 mg/kg doses over 72 hours)
Study: 10229733
Drug: DCLHb (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb (100 mg/kg)
Study: 17571284
Drug: Sitagliptin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 400 mg
Study: 17571284
Drug: Sitagliptin 25-400
Normalized name: SITagliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 25-400 mg
Study: 9707305
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg once daily for three days)
Study: 9707305
Drug: Cefaclor (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (30 mg/kg divided into three daily doses for ten days)
Study: 8585766
Drug: Acetaminophen (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg every 4 h)
Study: 8585766
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg every 4 h)
Study: 8585766
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg per day)
Study: 8585766
Drug: Acetaminophen, Aspirin,
Normalized name: Acetaminophen, Aspirin, and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, Aspirin, and Prednisone (as a group)
Study: 2242782
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human leukocyte alpha-interferon 10(6) IU/g
Study: 2242782
Drug: Topical human
Normalized name: thrombin topical human topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical human leukocyte alpha-interferon 10(4) IU/g
Study: 355958
Drug: Bromocriptine mesylate
Normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine mesylate (2.5 mg twice daily for 14 days postpartum)
Study: 21729808
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion to maintain BG level between 110 mg/dL and 126 mg/dL during surgery
Study: 6993163
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no insulin therapy)
Study: 19458605
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg once daily
Study: 14767445
Drug: Omalizumab (0.016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (0.016 mg/kg per IgE (IU/mL))
Study: 11027921
Drug: Cocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (20 mg or 40 mg)
Study: 31955461
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (c‐PDT) with blue light
Study: 27209269
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of renal replacement therapy (RRT) within 8 hours of diagnosis (n=112)
Study: 27209269
Drug: Delayed initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed initiation of renal replacement therapy (RRT) within 12 hours of stage 3 AKI or no initiation (n=119)
Study: 27373900
Drug: HPV 16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV 16/18 AS04-adjuvanted vaccine
Study: 18054942
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment (3 years)
Study: 15630733
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg twice a week
Study: 30651138
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg once daily for 2 weeks
Study: 30651138
Drug: Placebo 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 200 mg once daily for 2 weeks
Study: 23014927
Drug: Intravenous atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous atrial natriuretic peptide (ANP) at 0.03 μg/kg/min
Study: 23014927
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (NTG) at 0.3 μg/kg/min
Study: 16796836
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline and heparin (Control)
Study: 12697853
Drug: Bestatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin (30 mg daily for 2 years)
Study: 12504395
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 2 years)
Study: 9117020
Drug: ABT‐761 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐761 (200 mg)
Study: 3537093
Drug: Individually polymerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually polymerized grass (IPG) immunotherapy with an accelerated dosage schedule (24,000 PNU over 9 weekly visits)
Study: 3537093
Drug: Individually polymerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually polymerized grass (IPG) immunotherapy
Study: 27733403
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg vitamin D3/d supplementation for 20 weeks
Study: 27733403
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg vitamin D3/d supplementation for 20 weeks
Study: 27733403
Drug: 0 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 μg vitamin D3/d (placebo) for 20 weeks
Study: 18789844
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg/day)
Study: 24850229
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received fluvoxamine (100 mg/day for the first 4 weeks, then 200 mg/day for the rest of the trial)
Study: 22885123
Drug: Phacoemulsification and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phacoemulsification and intraocular lens implant (phaco/IOL)
Study: 18192132
Drug: daily‐dose blister
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily‐dose blister packaging (Pill Calendar)
Study: 18192132
Drug: traditional bottles
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional bottles of loose tablets
Study: 776090
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide cream
Study: 21975580
Drug: THC (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (500 μg/kg body weight)
Study: 16019368
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg testosterone gel
Study: 16019368
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg testosterone gel
Study: 16019368
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg testosterone gel
Study: 8027217
Drug: Alprazolam (APZ)
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam (APZ) 2 mg orally
Study: 2692094
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg tid for 10 days)
Study: 2692094
Drug: Amoxycillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (1 g tid for 10 days)
Study: 31522785
Drug: l-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine infusion (1.2 μmol kg-1 min-1)
Study: 28796316
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 8 mg/kg
Study: 11928800
Drug: Vaccine therapy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine therapy
Study: 16006888
Drug: Nilutamide (antiandrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilutamide (antiandrogen therapy)
Study: 16006888
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (vaccine + nilutamide)
Study: 16006888
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (vaccine + nilutamide) after vaccine arm progression
Study: 12094191
Drug: Heparin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dosing of approximately 14 U/kg/h or an aPTT of approximately 70 seconds
Study: 12094191
Drug: Heparin dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dosing
Study: 12094191
Drug: Heparin resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin resistance with high dosages and low aPTT values
Study: 7670342
Drug: Millimetric electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Millimetric electromagnetic radiation (MER) therapy using wavelengths of 6.4 and 7.1 mm on a YAVOR device for 10 sessions
Study: 7670342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (specific drugs without MER therapy)
Study: 7004051
Drug: Oral PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral PGE2 (0.5 mg initially, followed by 1.0 mg every hour for up to 24 hours)
Study: 7004051
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (starting at 5 mIU/min, increasing to 20 mIU/min)
Study: 331402
Drug: Oral PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral PGE2
Study: 7004051
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PGE2 and oxytocin)
Study: 25526906
Drug: Daidzein (500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daidzein (500 mg/kg concentrate)
Study: 23648344
Drug: Methylprednisolone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (0.8 mg×kg(‐1)×d(‐1)) therapy
Study: 21819161
Drug: Pantoprazole-Mg 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole-Mg 40 mg once daily for 8 weeks
Study: 21819161
Drug: Pantoprazole-Na 40
Normalized name: Pantoprazole Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole-Na 40 mg once daily for 8 weeks
Study: 21819161
Drug: Pantoprazole-Mg 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole-Mg 40 mg once daily for 4 weeks
Study: 21819161
Drug: Pantoprazole-Na 40
Normalized name: Pantoprazole Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole-Na 40 mg once daily for 4 weeks
Study: 10724056
Drug: Biweekly directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly directly observed preventive therapy with a $5 monetary incentive
Study: 10724056
Drug: Biweekly directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly directly observed preventive therapy using a peer health adviser
Study: 8956924
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VGB and CBZ
Study: 1551748
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg slow‐release co‐dergocrine mesylate administered once daily for 6 weeks
Study: 1551748
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg slow‐release co‐dergocrine mesylate
Study: 3873389
Drug: Oral, nonabsorbable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, nonabsorbable antibiotics (gentamicin + vancomycin + nystatin or neomycin + colistin + nystatin)
Study: 3873389
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral, nonabsorbable antibiotics)
Study: 3873389
Drug: Oral, nonabsorbable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, nonabsorbable antibiotics
Study: 31618127
Drug: GC4419 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC4419 90 mg
Study: 31618127
Drug: GC4419 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC4419 30 mg
Study: 27871280
Drug: Stereotactic radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereotactic radiation therapy (n=55)
Study: 20159245
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Budesonide, Nedocromil, Placebo)
Study: 16080282
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (FT) 3 g every 10 days for 6 months
Study: 7702152
Drug: Pre-operative oral
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative oral fluids (water)
Study: 363484
Drug: Celestone Chronodose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celestone Chronodose (subacromial injection)
Study: 363484
Drug: Celestone Chronodose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celestone Chronodose (gluteal injection)
Study: 31779925
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure reduction with diuretics
Study: 31779925
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure reduction with diuretics
Study: 29872803
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g high MW (HMW) barley β-glucan
Study: 29872803
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g low MW (LMW) barley β-glucan
Study: 29872803
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g low MW (LMW) barley β-glucan
Study: 21130977
Drug: isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isosorbide mononitrate (ISMN) 60 mg
Study: 21130977
Drug: losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 100 mg + ISMN 15 mg
Study: 21130977
Drug: losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 100 mg + ISMN 60 mg
Study: 11581232
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g iv bd
Study: 11581232
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g iv tds
Study: 9699698
Drug: Psychosocial occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial occupational therapy
Study: 7931739
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to a community physician, monthly 10‐minute work‐site counseling sessions including blood pressure readings, and personalized mailings
Study: 626273
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four tablets)
Study: 26559740
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using InGaAlP (660 nm-100 mW-4J/cm2) laser diode.
Study: 26559740
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no treatment).
Study: 26559740
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT).
Study: 25226108
Drug: Physical function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical function assessment using the Nottingham Extended Activities of Daily Living
Study: 17894335
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of apomorphine hydrochloride for 5 days
Study: 10199772
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 5 days
Study: 17894335
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of apomorphine hydrochloride
Study: 17894335
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of apomorphine hydrochloride and placebo
Study: 15041714
Drug: BMS‐275291 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐275291 (1200 mg/day)
Study: 11585606
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of T enanthate i.m. weekly for 8 weeks (active group)
Study: 11585606
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of sodium chloride i.m. weekly for 8 weeks (placebo group)
Study: 11585606
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg T enanthate i.m. bi-weekly for 8 weeks (hypogonadal group)
Study: 177372
Drug: alternating treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: alternating treatment of pivmecillinam and pivampicillin
Study: 22101426
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention focusing on self-management, delivered by a clinical pharmacist, with structured education about COPD and management of its symptoms.
Study: 19453396
Drug: H5 live
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5 live influenza vaccine (A/17/Duck/Potsdam/86/92 (H5N2)), administered intranasally in two doses 21 days apart.
Study: 15570576
Drug: Tolterodine (TOL)
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine (TOL) 4 mg daily for 8 weeks
Study: 12882824
Drug: Placebo oleic
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo oleic acid dietary supplement
Study: 3155806
Drug: Ceftriaxone (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (125 mg, 0.5 mL injection)
Study: 3155806
Drug: Spectinomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin (2 g injection)
Study: 29248640
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg for 6 months (n = 51)